Because some studies have found TP53 mutations in poorly differentiated and undifferentiated thyroid carcinomas but not in benign tumors, and only in a few well-differentiated thyroid cancers, it has been suggested that mutational inactivation of TP53 occurs at a late stage of tumor progression, contributing to the development of metastatic forms [12]. This evidence concerns the gene TP53 and benign neoplasm.